huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Phase-1-trial-of-human-chimeric-antigen-receptor-modified-t-cells-hucart-meso-administered-in-combination-with-vcn-01-in-patients-with-pancreatic-and-serous-epithelial-ovarian-cancer
| Principal Investigator | Phase | Penn Study Number | Clinicaltrials.gov ID |
|---|---|---|---|
| Janos Tanyi, MD PhD | 1 | UPCC03821 | NCT05057715 |
Purpose
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
Check Eligibility For This Trial
To inquire about participating in this study, please contact CareBox, Penn Medicine's Clinical Trial information Service.